Nephrocare Health Services Limited has announced a strategic asset acquisition in the Philippines through its subsidiary company. The healthcare services provider disclosed the transaction details to stock exchanges as part of its regulatory compliance obligations.

Asset Acquisition Details

Nephrocare Health Care Services Philippines Inc., a step-down wholly-owned subsidiary of Nephrocare Health Services Limited, has entered into an Asset Transfer Agreement with Laurel Kidney Care Dialysis Centre Inc. The agreement, dated February 12, 2026, involves the acquisition of identified assets relating to a dialysis center located at Laurel, Batangas, Philippines.

Regulatory Compliance and Disclosure

The company made the disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The information was communicated to both BSE Limited (Scrip Code: 544647) and National Stock Exchange of India Limited (Scrip Symbol: NEPHROPLUS).

Transaction Structure and Terms

The asset acquisition focuses specifically on dialysis center operations, aligning with Nephrocare's core healthcare services business. Key aspects of the transaction include:

• Purpose: Acquisition of dialysis center assets through Asset Transfer Agreement
• Special Rights: No special rights are associated with the agreement
• Related Party Status: The transaction does not fall within related party transactions
• Relationship: The seller is not related to the promoter/promoter group, while the purchaser is a step-down wholly-owned subsidiary

Corporate Governance

The disclosure was signed by Kishore Kathri, Company Secretary & Compliance Officer (ICSI M. No. F9895), ensuring proper corporate governance protocols were followed. The company has also made the information available on its official website at www.nephroplus.com , maintaining transparency with stakeholders.

This acquisition represents Nephrocare's continued expansion in the Philippines market, strengthening its dialysis care services network in the region through strategic asset acquisitions.

Nephrocare Health Services Limited has submitted its quarterly monitoring agency report for the period ended December 31, 2025, providing detailed insights into the utilization of proceeds from its recent Initial Public Offer. The healthcare service provider, which operates dialysis clinics across India, completed its IPO in December 2025 and is now reporting on the deployment of funds as mandated by regulatory requirements.

IPO Proceeds Overview

The company successfully raised gross proceeds of Rs 3,534.05 million through its IPO, which was conducted from December 10, 2025, to December 12, 2025. After deducting issue expenses of Rs 282.52 million, the net proceeds available for utilization amount to Rs 3,251.53 million.

The IPO proceeds were earmarked for three primary objectives: capital expenditure for opening new dialysis clinics (Rs 1,291.06 million), repayment of borrowings (Rs 1,359.99 million), and general corporate purposes (Rs 600.48 million).

Utilization During Q3FY26

During the quarter ended December 31, 2025, Nephrocare Health Services utilized Rs 904.99 million from the IPO proceeds, exclusively toward the repayment of working capital loans. This represents partial utilization of the Rs 1,359.99 million allocated for debt repayment purposes.

The monitoring agency report, prepared by Crisil Ratings Limited, confirms that all utilization was in accordance with the disclosures made in the offer document, with no deviations observed.

Deployment of Unutilized Funds

The company has deployed the unutilized proceeds totaling Rs 2,629.06 million in various fixed deposits with HSBC Bank and maintained a balance in its public issue account with Axis Bank. The fixed deposits carry an interest rate of 5.00% and have maturity dates of January 6, 2026, and January 7, 2026.

Regulatory Compliance and Monitoring

The monitoring agency report has been prepared in compliance with Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Regulation 41 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Crisil Ratings Limited, serving as the monitoring agency, has confirmed that there are no material deviations from the stated objects of the issue.

The report indicates that no government or statutory approvals were required for the current utilization, and no favorable or unfavorable events have been identified that would materially affect the viability of the stated objects. The company's management has provided necessary undertakings and certifications, which have been peer-reviewed by independent chartered accountants.

Future Deployment Plans

While the company has not yet commenced utilization of funds allocated for capital expenditure toward new dialysis clinics or general corporate purposes, the monitoring report does not indicate any delays in implementation. The company had originally planned to establish 167 new dialysis clinics across India using the allocated capital expenditure funds, spanning fiscal years 2026, 2027, and 2028.